Molson Coors OKs $2 billion buyback program, targets long-term sales growth in the low single digits
Molson Coors Beverage Co. (TAP) on Tuesday said its board had cleared a five-year, $2 billion stock buyback program and said it was "on track" to deliver its second straight year of sales and profit growth. The remarks were made in connection with the brewer's 2023 strategy day in New York. Longer term, executives said they expected "low-single digit" annual net sales growth when factoring out currency fluctuations, with "high-single-digit" yearly "underlying" per-share profit growth. Executives said a bigger push toward more premium beverages would help drive that growth, as well as an expansion beyond beer. They said they expected high-single digit constant-currency sales growth for 2023, but did not offer specific forecasts for 2024. "Over the past few years, long before controversy upended the U.S. beer industry, we changed how we invest, market, and operate, and we changed our future," Chief Executive Gavin Hattersley said, adding that the company had been "turned around." Shares fell 1.6% on Tuesday.
-Bill Peters
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
10-03-23 1605ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk